Acute On Chronic Liver Failure (ACLF) Market Size
Market Size in USD Bn
CAGR5.3%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 5.3% |
| Market Concentration | High |
| Major Players | Promethera Biosciences, Beijing Continent Pharmaceutical Co, Ltd, Cellaion SA, Versantis, Novartis and Among Others |
please let us know !
Acute On Chronic Liver Failure (ACLF) Market Analysis
The Global Acute On Chronic Liver Failure (ACLF) Market is estimated to be valued at USD 4.2 Bn in 2024 and is expected to reach USD 6.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031. ACLF is a complex liver disease associated with high short-term mortality. The increasing prevalence of chronic liver diseases such as alcoholic liver disease and non-alcoholic fatty liver disease is expected to drive the market growth over the forecast period.
The Acute on Chronic Liver Failure Market is witnessing positive trends which are expected to drive growth during the forecast period. There is an increased adoption of novel diagnostic tools and emergence of combination therapies for improved treatment outcomes of ACLF patients. Furthermore, the presence of strong product pipeline with drugs in late stages of clinical trials and growing research funding & investments for development of innovative treatment options for ACLF will further support the market growth in the coming years.